Premium
TAMOXIFEN USE, OESTROGEN BINDING AND SERUM LIPIDS IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER
Author(s) -
Ingram David
Publication year - 1990
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1990.tb07454.x
Subject(s) - medicine , tamoxifen , breast cancer , triglyceride , coronary heart disease , endocrinology , lipid metabolism , cholesterol , cancer , postmenopausal women , oncology
Tamoxifen is widely used in the management of breast cancer, including long‐term use in women with early disease to reduce recurrence and mortality. Although remarkably side‐effect free, concern has been expressed that its anti‐oestrogen activity may extend to lipid metabolism and so result in the premature development of coronary heart disease. In a study of breast cancer patients, those taking Tamoxifen tended to have lower cholesterol concentrations (predominantly low‐density lipoprotein cholesterol) and raised triglyceride concentrations. These changes are likely to be protective for coronary heart disease, suggesting Tamoxifen has an oestrogenic rather than anti‐oestrogenic effect as regards lipid metabolism.